Our findings pinpoint potential therapeutic targets for mitigating RGC loss in glaucoma, underscoring the pivotal role of RIP1 in RGC death and optic nerve damage, and offer novel perspectives for developing targeted glaucoma interventions. Here, RIPK1 is linked to glaucoma.